How has been the historical performance of Rossari Biotech?

Answer:The historical performance of Rossari Biotech shows a consistent growth trajectory in net sales and profits over the years.

Breakdown:
Rossari Biotech has demonstrated significant growth in net sales, increasing from 600.09 Cr in March 2020 to 2,080.29 Cr in March 2025. This upward trend is reflected in total operating income, which rose from 709.35 Cr in March 2021 to 2,080.29 Cr in March 2025. The company's operating profit (PBDIT) also improved, reaching 269.08 Cr in March 2025, up from 108.46 Cr in March 2020. Profit before tax followed a similar pattern, climbing from 88.06 Cr in March 2020 to 184.21 Cr in March 2025, while profit after tax increased from 65.47 Cr to 135.40 Cr during the same period. The company's total assets grew from 471.46 Cr in March 2020 to 1,885.67 Cr in March 2025, indicating a strong asset base. Total liabilities also rose, from 471.46 Cr to 1,885.67 Cr, primarily due to increased borrowings. Cash flow from operating activities improved significantly, reaching 137.00 Cr in March 2025, compared to 56.00 Cr in March 2020, while the closing cash and cash equivalents increased to 44.00 Cr in March 2025 from 29.00 Cr in March 2020. Overall, Rossari Biotech's financial performance reflects robust growth and operational efficiency over the years.